Cellceutix Corp. has signed an agreement with Girindus America, Inc. for the manufacture of Kevetrin API. Kevetrin is being developed to treat certain cancers. The company recently reported encouraging results in animal models of drug resistant lung cancers. Terms of the agreement were not disclosed. “This is a big step toward our short-term goal of filing for an investigational new drug exemption (IND) with the FDA,” said George Evans, chief executive officer of Cellceutix. “We w...